Great PR sifting through
PharmAust Limited, soon to be rebranded as Neurizon Therapeutics, reports a promising year with significant clinical advancements, particularly the positive Phase 1 study results of their drug candidate MPL for ALS treatment. The company, emboldened by the Orphan Drug Designation from the FDA and the potential OMPD from the EMA, is poised to enter the HEALEY ALS Platform Trial, which could accelerate FDA approval. With a strong financial backing and a refreshed Board, PharmAust is confidently navigating towards a transformative future in neurodegenerative disease treatment.
Great PR sifting through PharmAust Limited, soon to be rebranded...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $98.34M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.0¢ | 20.0¢ | $30.59K | 152.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 100626 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 10.39am 12/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |